Skip to main content

Table 1 Ongoing studies of tezepelumab in patients with asthma and healthy volunteers

From: Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?

ClinicalTrials.gov identifier Estimated start and completion dates Patient population Phase Primary outcome
NCT02698501
(UPSTREAM)
2016–2019 40 adults with asthma requiring ICS (± LABA) 2 Mannitol PD15
NCT03989544
(PATH-BRIDGE)
2019–2019 315 healthy adults 1 Pharmacokinetics of SC administration via accessorized pre-filled syringe or autoinjector compared with vial and syringe
NCT03968978
(PATH-HOME)
2019–2020 216 adults and adolescents with severe asthma 3 Successful SC administration via accessorized pre-filled syringe or autoinjector at home versus in the clinic
NCT03347279
(NAVIGATOR)
2019–2020 1038 adults and adolescents with severe, uncontrolled asthma, taking medium- to high-dose ICS and at least one additional asthma controller with or without OCS 3 Annualized asthma exacerbation rate
NCT03406078
(SOURCE)
2018–2020 150 adults with oral corticosteroid-dependent asthma (Americas, Europe) 3 Reduction in daily OCS dose
NCT03688074
(CASCADE)
2018–2020 116 adults with inadequately controlled moderate-to-severe asthma, taking ICS and at least one additional asthma controller 2 Number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies
NCT03706079
(DESTINATION)
2019–2022 966 adults and adolescents with severe, uncontrolled asthma 3 Exposure-adjusted incidence of adverse events and serious adverse events
NCT04048343
(NOZOMI)
2019–2021 66 Japanese adults and adolescents with inadequately controlled severe asthma 3 Rate of adverse events
NCT03927157
(DIRECTION)
2019–2023 396 Chinese adults with severe, uncontrolled asthma taking medium- to high-dose ICS and at least one additional asthma controller with or without OCS 3 Annualized asthma exacerbation rate
  1. ICS  Inhaled corticosteroids, LABA Long-acting β2 agonist, OCS Oral corticosteroids, PD15 Provoking dose to induce a 15% fall in forced expiratory volume in 1 s, SC  Subcutaneous